Lv1
40 积分 2021-12-04 加入
Dermatologic Adverse Events of Checkpoint Inhibitors: What an Oncologist Should Know
1年前
已完结
Dermatologic Adverse Events of Checkpoint Inhibitors: What an Oncologist Should Know
1年前
已关闭
Dermatologic Adverse Events of Checkpoint Inhibitors: What an Oncologist Should Know
1年前
已关闭
CTLA-4 and PD-1 Pathways
1年前
已完结
Mécanismes physiopathologiques des effets secondaires des immunothérapies par anticorps anti-CTLA-4, anti-PD-1 et anti-PD-L1 dans le traitement du cancer
1年前
已完结
Supramolecular Nanoagent as a dual-blocked thermoresistance inhibitor for effective mild-temperature photothermal therapy
1年前
已完结
皖公网安备34019202002308
